Related references
Note: Only part of the references are listed.Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
K. K. Matthay et al.
BRITISH JOURNAL OF CANCER (2010)
Usefulness of I-123-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial
Gregory A. Wiseman et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
123I-mIBG Scintigraphy in Patients With Known or Suspected Neuroblastoma: Results From a Prospective Multicenter Trial
Terry A. Vik et al.
PEDIATRIC BLOOD & CANCER (2009)
The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastorna >1 year of age on a high-risk treatment protocol:: Results of the German Neuroblastoma Trial NB97
Matthias Schmidt et al.
EUROPEAN JOURNAL OF CANCER (2008)
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
Julia A. Messina et al.
PEDIATRIC BLOOD & CANCER (2006)
Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma
HM Katzenstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy
BH Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
